Target identification and validation is one of the biggest challenges in the pharmaceutical industry, with many promising treatments failing in the clinic due to efficacy or target-related safety issues. The reason is usually that the underlying hypothesis turns out to be wrong, or there are unwanted consequences of modulating the target. Due diligence around a target early on, can make the difference between success and failure of a program.
In this video, Dr. Kenneth Barr, Syngene's Sr. Vice President of Discovery Services, answers some of the frequently asked questions about Syngene’s in-silico target assessment services. Syngene specialize in in silico-based identification, selection, analysis, and prioritization of potential drug targets by using a combinatorial approach of biology and bioinformatics.